Novel systemic therapies for breast cancer

This publication has 41 references indexed in Scilit:

• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation
  Journal of Biological Chemistry, 2003
• Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm
  Journal of Clinical Oncology, 2003
• Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
  Annals of Oncology, 2003
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)
  Endocrinology, 2001
• Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells
  Endocrinology, 1998
• Aberrant function of the Ras signal transduction pathway in human breast cancer
  Breast Cancer Research and Treatment, 1995
• The influence of chemotherapy on survival after recurrence in breast cancer—a population-based study of patients treated in the 1950s, 1960s and 1970s
  European Journal Of Cancer, 1993
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987
• Tumor Angiogenesis: Therapeutic Implications
  New England Journal of Medicine, 1971